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Alzheimer’s disease is a neurodegenerative disease characterized by disrupted memory,
learning functions, reduced life expectancy, and locomotor dysfunction, as a result of
the accumulation and aggregation of amyloid peptides that cause neuronal damage
in neuronal circuits. In the current study, we exploited a transgenic Drosophila
melanogaster line, expressing amyloid-β peptides to investigate the efficacy of a newly
synthesized acetylcholinesterase inhibitor, named XJP-1, as a potential AD therapy.
Behavioral assays and confocal microscopy were used to characterize the drug effect
on AD symptomatology and amyloid peptide deposition. The symptomatology induced
in this particular transgenic model recapitulates the scenario observed in human AD
patients, showing a shortened lifespan and reduced locomotor functions, along with
a significant accumulation of amyloid plaques in the brain. XJP-1 treatment resulted
in a significant improvement of AD symptoms and a reduction of amyloid plaques
by diminishing the amyloid aggregation rate. In comparison with clinically effective AD
drugs, our results demonstrated that XJP-1 has similar effects on AD symptomatology,
but at 10 times lower drug concentration than donepezil. It also showed an earlier
beneficial effect on the reduction of amyloid plaques at 10 days after drug treatment,
as observed for donepezil at 20 days, while the other drugs tested have no such
effect. As a novel and potent AChE inhibitor, our study demonstrates that inhibition of
the enzyme AChE by XJP-1 treatment improves the amyloid-induced symptomatology
in Drosophila, by reducing the number of amyloid plaques within the fruit fly CNS.
Thus, compound XJP-1 has the therapeutic potential to be further investigated for the
treatment of AD.
Keywords: Alzheimer’s disease, Aβ42, acetylcholinesterase, acetylcholinesterase inhibitors, Drosophila
melanogaster, amyloid aggregation 3
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INTRODUCTION
Alzheimer’s disease (AD) is recognized as the worldwide
leading cause of dementia, with 5.8 million patients currently
affected in the US, with this number expected to double by
2050 (Alzheimer’s Association, 2019). Alzheimer’s disease is a
progressive neurodegenerative disease with sufferers presenting
an array of characteristic phenotypes including amyloid plaques,
neurofibrillary tangles, oxidative stress, neuroinflammation, and
reduction of cholinergic marker levels, which lead to neuronal
death and brain atrophy (Hampel et al., 2018). Amyloid
plaques are formed of amyloid-β peptides, secreted by neurons,
which form insoluble toxic aggregates that lead to local
neuroinflammatory and neurodegenerative responses (Sharma
et al., 2019). The amyloidogenic pathway can generate amyloid-
β peptides of various lengths, ranging from 17 to 42 amino
acids (Wang et al., 2015). Sequential cleavages of the amyloid
precursor protein (APP) performed by β- and γ-secretase is
required to generate neurotoxic amyloid-β peptides, which is
primarily 40 or 42 amino acids in length (O’Brien and Wong,
2011). On the other hand, neurofibrillary tangles are composed
of a number of fused Tau protein, due to the presence of
a hyperphosphorylated form of Tau (Zhang et al., 2016a). In
normal physiological conditions, Tau is required to stabilize
and promote microtubule polymerization, while in AD, Tau is
hyperphosphorylated, leading to a disruption of microtubule
architecture and stability (Sharma et al., 2019).
To date, the AD triggering mechanism is not fully understood,
with the exception of genetic mutations causing familial AD
where the E693G mutation (hereafter referred to as Arctic
mutation) of the APP protein is one of the most severe, due
to the rapid aggregation of mutant amyloid-β peptides in the
brain (Nilsberth et al., 2001; Norlin et al., 2012; Mendez, 2017).
However, according to the cholinergic hypothesis, a drop in the
level of cholinergic markers, acetylcholine and acetyl-transferase,
is the starting point of AD pathogenesis in the brain (Ramos-
Rodriguez et al., 2013; Hampel et al., 2018). Acetylcholine plays
a crucial role in memory and learning circuits, which undergo
a severe neurodegeneration during AD progression (Mesulam,
2013; Whitehouse et al., 1981). Furthermore, depletion of
acetylcholine is linked with an aberrant vasomotor control of the
blood–brain barrier (hereafter referred to as BBB), leading to a
defective clearance of the amyloid peptides (Hunter et al., 2012).
The Food and Drug Administration (FDA) has currently
approved three acetylcholinesterase (AChE) inhibitors for AD
treatment; these therapies increase the acetylcholine levels in an
attempt to improve the patient’s cognitive functions (Ramos-
Rodriguez et al., 2013; Shrivastava et al., 2019). Therapy with
AChE inhibitors has clinically resulted in modest disease-
modifying effects and beneficial effects in the psychiatric
symptomatology (Tayeb et al., 2012). Such therapies also delayed
by at least 1 year nursing home placement of AD patients,
resulting in a significant reduction of the economic burden
experienced by patients’ families (Wattmo et al., 2011). It
has been suggested that AChE enzyme facilitates amyloid
aggregation by acting as a nucleation point, while treatment
with inhibitors reportedly reduced the aggregation rates and
potentially prevented or at least delayed the formation of
larger plaques (Shrivastava et al., 2019). Thus, development
of novel AChE inhibitors that would be able to increase the
level of acetylcholine, and therefore improve the cognitive
symptomatology and also reduce the available AChE surface
for amyloid interaction and subsequent aggregation, remains a
promising therapeutic strategy for AD patients.
The FDA has also approved an n-methyl D-aspartate
(NMDA) receptor antagonist, named memantine, as an AD
therapy. Several reports have highlighted the involvement of the
glutamatergic system in AD disease progression (Tayeb et al.,
2012). Memantine is currently administrated either alone, or in
combination with donepezil, in patients with severe cases of AD,
despite some disagreeing reports on the further beneficial effects
of this combined therapy (Parsons et al., 2013).
Testing the efficacy of AD drugs is particularly complicated by
the complex and not fully understood part of the disease. Several
models, such as mice, zebrafish, Drosophila melanogaster, and
cell culture, have been explored to study both the mechanistic
biology behind AD pathogenesis and for drug screening purposes
(Drummond and Wisniewski, 2017). However, the progress of
new drug discovery and development has been slow due to the
limited availability of in vitro and in vivo models that recapitulate
AD pathologies, together with neuronal death. This fundamental
limit often results in a failure during clinical trials of potential
AD therapies, since the results in pre-clinical studies are not
confirmed in AD patients. As a result, since 2003, 100% of
drug candidates for AD treatment have failed in clinical trials
(Cummings et al., 2019). In recognition of the fact that the AD
animal models have only limited predictive value for how drugs
behave in AD humans, pathologically and genetically relevant
models are therefore required for informing the design of more
effective therapies.
The common fruit fly D. melanogaster has been explored
as an AD model, as first reported in 2005 (Crowther et al.,
2005). Fruit fly AD models have been exploited to study both
pathways involved in AD pathogenesis and to test several
potential AD therapies, such as peptides, radiations, natural-
derived compounds, and AChE inhibitors (Luo et al., 1992;
Zhang et al., 2016b; Pham et al., 2018; Ali et al., 2019; Hwang et al.,
2019; Kizhakke et al., 2019; Miyazaki et al., 2019; Zhong et al.,
2019; Ogunsuyi et al., 2020). In addition to this, the models offer
the possibility to study some human AD patient features, such as
reduced lifespan, locomotor defects, and cognitive impairment.
The exploitation of the lifespan assay has been extensively used
to define the effects of compounds on the reduced survival time
caused by the expression of toxic AD proteins. Moreover, the
climbing assay allows one to define any locomotor defects caused
by AD gene expression and the possibility to detect amelioration
following treatment (Kohlhoff et al., 2011; Nichols et al., 2012;
Pham et al., 2018; Ali et al., 2019).
However, it has to be mentioned that the role of acetylcholine
in invertebrates has some peculiar differences to that observed
in the vertebrate organisms. In the fruit fly, acetylcholine is the
primary excitatory neurotransmitter in the CNS, and the primary
transmitter of sensory neurons (Lee and O’Dowd, 1999). In
addition to this, acetylcholine is not present in the neuromuscular
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junction (hereafter referred to as NMJ) as it is in the vertebrates.
Instead, the NMJ of fruit flies or invertebrates is regulated
by glutamate. Despite this difference in the NMJ physiology,
acetylcholine in the fruit fly regulates jumping, geotaxis, and
motion detection stimuli (Hou et al., 2003; Takemura et al.,
2013). The fruit fly AChE folding structure is also similar to
the vertebrate enzyme, with variations observed mainly in the
peripheral anionic site (PAS) but not in the catalytic active site
(CAS) (Wiesner et al., 2007).
Drosophila melanogaster offers several advantages as a model
organism, such as a well-defined genome, the possibility to
study hundreds of animals simultaneously, and low cost of
maintenance (Sivanantharajah et al., 2019; Tue et al., 2020).
Moreover, the easily accessible Drosophila brain allows one
to image and quantify amyloid plaque deposition in amyloid
transgenic models, along with the possibility to investigate
selected areas of the brain involved in cognitive processes, such
as the mushroom bodies (Hwang et al., 2019; Zhong et al., 2019).
In the work presented here, we drive the expression of the
APP gene carrying the Arctic mutation in D. melanogaster
(hereafter referred to as Aβarc flies) as previously reported
(Sandin et al., 2016). The Arctic mutation was initially genotyped
from a Swedish family with a history of early-onset familial AD
(Nilsberth et al., 2001), causing the production of toxic amyloid-
β peptides (Norlin et al., 2012). The Arctic mutation has been
linked to a faster amyloid aggregation rate both in vitro and
in vivo (Dahlgren et al., 2002; Englund et al., 2007). In addition,
amyloid-β peptides carrying the Arctic mutation form fibrils
whose diameter is directly proportional to neuronal cell death
rate (Dahlgren et al., 2002), leading to the early onset of the
AD symptoms in human patients, including cognitive disabilities,
memory impairment, and locomotor defects (Dahlgren et al.,
2002; Basun et al., 2008). Following extensive previous in vitro
studies, here we present biological evaluation of our previously
reported novel AChE inhibitor (Wang et al., 2015), named XJP-1,
using the Aβarc DrosophilaAD model. XJP-1 is a naturally derived
product, with part of the structure derived from a compound
isolated in the peel of Musa sapientum L., which has shown
an excellent inhibitory activity against AChE, along with a high
specificity for AChE over butyrylcholinesterase (BuChE) (Wang
et al., 2015, 2018). In addition to this, XJP-1 was predicted to
have high BBB permeability in docking studies and no toxicity
on neurotypic SH-SY5Y cells (Wang et al., 2015, 2018).
Here, we examined whether XJP-1, along with current FDA-
approved AD therapies, can improve the symptoms induced by
the Arctic mutation in D. melanogaster, and reduce amyloid
deposition in the adult fly brain at different time points.
Abbreviations: AChE, Acetylcholinesterase; AD, Alzheimer’s disease; APP,
amyloid precursor protein; Aβarc, amyloid-β Arctic; BACE1, β-site APP-cleaving
enzyme 1; BuChE, butyrylcholinesterase; BSA, bovine serum albumin; BBB,
blood–brain barrier; CAS, catalytic active site; elav, embryonic-lethal abnormal
visual; FDA, Food and Drug Administration; GSK3-β, Glycogen synthase kinase
3 beta; HFIP, hexafluoroisopropanol; M + D, memantine + donepezil; M + X,
memantine + XJP-1; NGS, normal goat serum; NMJ, neuromuscular junction;
NMDA, n-methyl D-aspartate; NMDAR, n-methyl D-aspartate receptor; PAS,
peripheral anionic site; RIPA, Radioimmunoprecipitation assay buffer; ThT,
thioflavin-T; UAS, upstream activating sequence.
MATERIALS AND METHODS
Reagents
AChE inhibitors donepezil, galantamine, and rivastigmine
were purchased from Sigma-Aldrich Ltd. NMDAR antagonist
memantine was purchased from Sigma-Aldrich Ltd. Drug
candidate XJP-1 was gifted by Prof. Jinyi Xu (China
Pharmaceutical University).
Fly Strains
The UAS-APPE693G (#33774) and elav-Gal4 (#458) flies were
purchased from Bloomington Drosophila Stock Centre Indiana.
Flies were kept at 25◦C in 25-ml plastic vials containing 5 ml
of standard fly food. elav-Gal4 virgin females were crossed with
UAS-APPE693G males, all stocks were kept at 25◦C, and the
female progeny was used for all the assays. Elav-Gal4 flies were
used as a wild-type (WT) control.
Fly Food Preparation
Flies were fed using the standard fly food recipe containing
(quantity for 1 L): 70.62 ml of golden syrup, 15.87 g of yeast,
9.12 g of soya flour, 67 g of cornmeal, 5.25 g of agar, and
711.25 ml of water. To add the drug of interest into the food,
an aliquot of the drug stock solution was dissolved in a volume
of water to 1/5th of the total food volume and mixed on the
magnetic stirrer for 2 min. Subsequently, once the temperature
has cooled to <80◦C, the diluted drug was added and mixed
in homogeneously. Compounds were dissolved at minimum
effective concentration, as 40 µM for XJP-1, 0.5 mM for
donepezil, 0.5 mM for galantamine, 0.1 mM for rivastigmine, and
0.5 mM for memantine. Combined therapies were administrated
at the same concentration as the monotherapy.
Lifespan Assay
Newly emerged flies aged 0–24 h were collected and placed into
fresh food vials containing 5 ml of fly food. Each vial contained
a total of 20 flies. At least 100 flies per genotype were analyzed.
Food vials containing the flies were kept horizontally and flies
were flipped 3 times/week, with the number of dead flies counted
at that time. Flies that escaped, died in the food, or became
trapped in the cotton bung were not taken into account.
Climbing Assay
WT and transgenic Drosophila locomotor functions were
measured by performing a climbing assay. Flies aged 0–24 h
were collected and placed into fresh food vials containing the
appropriate treatment. Each food vial contained up to 10 flies.
Vial containing flies were flipped three times a week, for a total of
3 weeks, and at this time, climbing performance was recorded as
follows: flies were moved into an empty 50-ml plastic tube, and
the number of flies that had climbed above the three cutoff lines
(40, 30, and 20 ml) was counted after 20 s. The results were then
calculated using the following formula:
Climbing Index = (percentage of total flies above the 40-ml
line) × 1
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+ (percentage of total flies between the 30-ml and 40-ml
lines) × 0.75
+ (percentage of total flies between the 20-ml and 30-ml
lines) × 0.50.
Immunohistochemistry
Adult flies were firstly anesthetized with CO2 and subsequently
killed in pure ethanol (100%). Brains were dissected in phosphate
buffered saline (PBS) and then fixed in 4% paraformaldehyde
(PFA) for 20 min at room temperature (RT). Tissues were then
washed three times in 1% PBS-Tween 20 (PBS-T) for 2 min, and
subsequently placed in 5% normal goat serum (NGS) in PBS-
T for 2 h at room temperature. After removing the 5% NGS-T,
the rabbit anti-Aβ42 primary antibody (#ab2539, Abcam plc.)
was added at a final concentration of 1:200 in 5% NGS-T and
left to incubate overnight at +4◦C. The primary antibody was
then washed three times with 1% PBS-T and subsequently the
goat anti-rabbit secondary antibody was added to a final 1:250
concentration. The sample was allowed to incubate for 1 h at
room temperature. Goat anti-rabbit 488 Alexa Fluor secondary
antibody (#A-11034; ThermoFisher Scientific) was then washed
three times with 1% PBS-T. Brain samples were then mounted
for confocal imaging exploiting a “bridge” structure to avoid
any sample damage caused by the coverslip. Two 0.1-mm thin
coverslips were attached to the glass slide at approximately 5 mm
distance to each other. Subsequently, 20 µl of mounting media
(90% PBS and 10% glycerol) was added in the gap between the
two coverslips. Samples were then placed into the mounting
media, and an additional cover slip to bridge the gap between
the two “pylon” coverslips. Samples were analyzed by confocal
microscopy within 24 h from mounting.
Confocal Imaging
All brain images were acquired using the Zeiss880 confocal
microscope. Laser power was set at 2.5%, gain at 520. Digital
offset was set at 200. The imaging acquisition speed was 1.03 s,
averaging two times per slice. For visualization purposes, the
figures presented have been made by setting the brightness value
to 30,000 and subsequently converting into 8-bit images.
Image Analysis
A macro was created in FIJI to identify and measure amyloid
spots in the images scanned with the confocal microscope. The
processing analysis was carried out using the following steps:
raw 16 bit confocal images were imported into FIJI; maximum
projection (focus stack flattening) was applied and a copy of this
image was created; the copy was used for object identification
and the creation of the mask; a Gaussian blur filter was applied
to the image to smooth the noise pixels; a threshold of 14,850–
61,890 was used to separate the plaque signals from the rest of the
image and from the background; the lower value of thresholding
14,850 was determined by using negative control and non-stained
areas of the brain. Top value was set just below the maximum
to avoid occasionally appearing large clumps of overexposed
areas; a mask was created based on the threshold areas; particle
analysis was carried out on the mask while fluorescence intensity
measurements were performed by redirecting the measure
function to the original image; the particle analysis was carried
out to generate size, intensity, and shape measurements of the
plaques; the number of particles (amyloid spots) was used to
characterize the effect of each treatment.
Western Blot
A total of 50 fly heads were dissected and frozen overnight
at -80◦C. Samples were then homogenized in 150 µl of RIPA
Lysis and Extraction Buffer (#89901, ThermoFisher Scientific).
Subsequently, each sample was centrifuged at 14,000g at 4◦C for
10 min, and the supernatant was then transferred into a fresh
new vial. Protein concentrations were quantified using Bradford
Assay Kit (#ab102535, Abcam, United Kingdom). According
to protein concentrations, samples were then dissolved in
4 × NuPage LDS Sample Buffer (#NP0007, Invitrogen) and
loaded into 4%–12% Bis-Tris Gel (#NP0322PK2, Invitrogen).
Following separation, proteins were transferred onto a 0.2-µm
nitrocellulose membrane (#1620150, Bio-Rad) using semi-dry
apparatus TransBlot Turbo (#1704150, Bio-Rad). Membranes
were then blocked in 5% bovine serum albumin (BSA) for 1 h at
room temperature and subsequently incubated overnight at 4◦C
with rabbit anti-Aβ42 primary antibody (#ab2539, Abcam plc)
at final 1:1000 concentration. Monoclonal Anti-β actin antibody
was used as loading control in Western Blot experiments
(#ab1801, AbCam plc.). Each membrane was then washed three
times in 5% TBS-T for 5 min and subsequently incubated
for 1 h at room temperature with goat-anti rabbit IgG H&L
(HRP) (#ab6721, AbCam plc.) secondary antibody at a final
concentration of 1:5000. Excess secondary antibody was then
discarded and membrane was washed three times using 5% TBS-
T. Each membrane was then imaged using Fujifilm LAS-4000
(Fujifilm). Results were then analyzed using FIJI.
Quantification of AChE-Induced Aβ42
Aggregation
Measurements of AChE-induced amyloid aggregation were
taken following the protocol previously reported (Jiang et al.,
2019). Briefly, hexafluoroisopropanol (HFIP)-treated E22G Aβ
peptides (#SP-Ab-11_0.1, JPT–Innovative Peptide Solution) were
dissolved in DMSO to reach a final 200 µM stock. The dissolved
peptides were subsequently centrifuged at 13,500g for 10 min,
and the supernatant was then transferred into a fresh vial and
used for the following experiments. To evaluate the aggregation
rate in the presence of AChE inhibitors, 2 µl of the compound of
interest (at the appropriate concentration) was added into each
vial, followed by 2 µl of 200 µM Aβ peptides stock, 20 µl of
AChE (#C3389, Sigma-Aldrich Ltd) (2 U/ml, in 1 × PBS at pH
8.0), and 76 µl 1 × PBS, pH 8.0. The reaction was then incubated
at room temperature (RT) for 24 h. Subsequently, 100 µl of 5 µM
Thioflavin T (#ab120751, ThT) was added into each vial. After 1-h
incubation at RT, fluorescence emission was recorded at 490 nm
with an excitation wavelength of 450 nm using a Tecan Spark
microplate reader. Results were then processed as previously
described by Jiang et al. (Jiang et al., 2019) using the subsequent
formula: (Fi - Fb)/(Fo - Fb) - 100, where Fi corresponds to amyloid
aggregation in the presence of peptides, AChE, AChE inhibitors,
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and ThT; Fo represents the amyloid aggregation in presence of
peptides, AChE, and ThT; and Fb corresponds to blank control
containing ThT only.
Statistical Analysis
All statistical analyses were performed using GraphPad Prism 9
software. Data obtained were firstly tested for normality using the
Shapiro–Wilk test. The Kaplan–Meier test was used to compare
different survival curves. The Kruskal–Wallis test, followed by
Dunn’s post hoc, was used to compare differences between
three or more groups in non-normally distributed data. The
ANOVA test was used to compare differences between three
or more groups of normally distributed samples. The Friedman
test, followed by Dunn’s post hoc test, was used to analyze
differences between three or more groups in the climbing assay.
Each experiment was performed in triplicate, and all results are
presented as mean ± standard error of the mean (SEM) or
mean ± standard deviation (SD). Results with a P-value < 0.05
were considered significant.
RESULTS
XJP-1 Treatment Improves Life
Expectancy in Aβarc Flies
In order to investigate the effect of the Aβarc mutation on
life expectancy, flies were firstly grown on food without
any therapy. Expression of amyloid peptides resulted in a
dramatic drop of mean survival time when compared to
WT flies (Figures 1A,B). To investigate the effects of XJP-
1 treatment on life expectancy, Aβarc flies were treated with
40 µM (as the minimum effective concentration) of the new
AChE inhibitor after testing a range of concentrations (10–
40 µM); 10 to 30 µM did not produce any significant
amelioration in pilot lifespan assay (data not shown). XJP-1
therapy resulted in a significant increase in the mean survival
time, 26. 74 days vs. 36.38 days (Table 1), of Aβarc flies
with around 40% of the entire population surviving after day
40 (Figures 1A,B). Comparable results were also recorded
with other FDA-approved AD drugs, including the AChE
inhibitors donepezil (30.76 days) (0.5 mM as the minimum
effective concentration), rivastigmine (31.49 days) (0.1 mM),
and the NMDAR antagonist memantine (32.61 days) (0.5 mM).
Galantamine (0.5 mM), however, had no significant effect
(Table 1). Among all the tested compounds, XJP-1 showed most
potent efficacy at a concentration of 40 µM, more than 10
times lower than observed for donepezil, on Aβarc survival time
(Figures 1A,B).
Since the FDA currently approves a combined therapy of
memantine and donepezil, we investigated whether XJP-1 and
memantine treatment would further enhance the results obtained
by XJP-1 alone. Both a combination of FDA-approved therapies
and XJP-1 plus memantine showed a significant improvement
of the Aβarc Drosophila lifespan (Figures 1A,B). However, no
significant difference was recorded when the combined therapies
were compared to the corresponding monotherapies (Table 1).
Locomotor Functions Improve Following
XJP-1 Treatment
The climbing assay is a behavioral test, based on negative geotaxis
against gravity, which is used to assess the locomotor function
in Drosophila (Nichols et al., 2012). With this assay, Aβarc
flies recorded a time-dependent worsening of climbing ability,
thereby faithfully recapitulating symptoms observed in human
patients (Figure 2A). Treatment with XJP-1 improved locomotor
function in Aβarc flies over 20 days, with the exception of days
5 and 21 of analysis (Figure 2B). The climbing performance
recorded in flies treated with XJP-1 were constantly twofold
better than the untreated Aβarc flies, with peaks at day 16 of
analysis when the treated group recorded a climbing score of
67.29 against 3.62 for the untreated groups (Table 1).
On the other hand, among the FDA-approved therapies,
only donepezil treatment showed results comparable to XJP-1,
recording a homogeneous climbing performance over the first
19 days of analysis, with a minimum of twofold improvement
of the locomotor performance, except for day 9 of analysis
(Figure 2C; Table 1).
Rivastigmine, galantamine, and memantine had a beneficial
effect that was limited only to the first 10 days of analysis
(Figures 2D–F). Aβarc flies treated with combined therapies
showed a significant improvement in locomotor function only
throughout the first 10 days of analysis, and at day 14 for XJP-
1 and memantine, therefore having a worse effect on locomotor
functions than donepezil and XJP-1 alone (Figures 2G,H,
Table 1).
XJP-1 Reduces the Number of Amyloid
Plaques in the Brain
The deposition, accumulation, and aggregation of amyloid
peptides in the central nervous system (CNS) is a crucial point
in the development of Alzheimer’s symptomatology. Using HFIP-
treated Aβ peptides, together with confocal microscopy, we found
Aβarc fly brains to possess large and extensively distributed
amyloid aggregates (hereafter referred to as amyloid spots) at
10 days post-eclosion (Figure 3A). To investigate whether flies
treated with XJP-1, or clinically available therapies, would present
any difference in amyloid pathology in the CNS, we imaged
Aβarc fly brains following 10 days of treatment (Figure 3A).
Subsequent quantification showed a significant reduction in
amyloid spot counts in flies treated with either XJP-1 or XJP-1 and
memantine combined. None of the clinically approved therapies
had similar results to the new AChE inhibitor (Figure 3B). To
further investigate whether there was a remarkable difference
in amyloid spot counts in those brain areas rich in cholinergic
neurons, we exploited the Fly Brain Observatory software to
determine areas of the brain that are rich in cholinergic neurons.
We found that mushroom bodies (Supplementary Figure 1A),
fan-shaped bodies (Supplementary Figure 1B), the medulla
(Supplementary Figure 1C), and optic lobes (Supplementary
Figure 1D), were rich in cholinergic neurons compared to other
areas, such as the antennal lobes (Supplementary Figure 1E)
and suboesophageal ganglion (Supplementary Figure 1F) (Xu
et al., 2020). Analysis of mushroom body and fan-shaped






















TABLE 1 | Data table.




Mean Mean P value vs.
Aβarc
Mean P value vs.
Aβarc
Mean P value vs.
Aβarc
Mean P value vs.
Aβarc
Mean P value vs.
Aβarc
Mean P value vs.
Aβarc
Mean P value vs.
Aβarc
Lifespan assay 26.74 36.38 < 0.0001 30.76 < 0.0001 31.49 < 0.0001 27.52 0.9994 32.61 0.0008 34.68 < 0.0001 31.98 0.0005
Climbing assay Day-2: 35.625 67.81 0.016 87.5 0.0003 87.083 0.0005 67.75 0.0511 67.868 0.041 37 0.932 72.6375 0.032
Day-5: 34.3329 40.86 0.0724 75 0.006 66.75 0.0003 86.008 0.0088 79.86 0.0005 71.25 0.0088 70.5145 0.0003
Day-7: 23.6085 50.08 0.04 38.5 0.028 56.223 0.0005 36.174 0.58 59.903 0.0006 68.26 0.0007 65.3487 0.0004
Day-9: 12.5175 38.278 0.0014 27.1 0.77 31.25 0.042 21.166 0.61 27.487 0.059 36.93 0.0056 29.8625 0.0071
Day-12: 9.5967 44.4 0.0008 29.5 0.019 24.438 0.58 31.832 0.0532 14.25 0.66 19.68 0.0839 10.685 0.7643
Day-14: 6.925 31.05 0.022 33.6 0.0047 0 0.865 21.583 0.0799 23.369 0.062 44.35 0.0006 20.7625 0.0664
Day-16: 3.6242 67.29 0.0002 49.7 0.0003 3.261 0.832 12.5 0.0527 23.369 0.052 11.84 0.054 0.06273 0.71
Day-19: 4.886 15.418 0.032 18.7 0.012 2 0.75453 5.556 0.93 7.293 0.057 5.313 0.513 0.24573 0.361
Day-21: 0.832 8.369 0.1734 8.13 0.0615 5.716 0.566 1.667 0.91 0 0.65 0 0.66 0 0.982
Amyloid spots (10 days) 987.5 362.3 0.0005 703.9 0.2691 773.1 0.5659 711.6 0.2961 639 0.1095 453 0.0035 886.3 0.984
Amyloid spots (20 days) 1137 383.5 < 0.0001 390.5 < 0.0001 525.7 0.0582 673.4 0.0657 373.5 < 0.0001 520.2 0.0002 528 0.0096
MB + FBS amyloid spots (10 days) 465.3 196 0.0034 358.8 0.5605 325.4 0.2709 296 0.1204 307.6 0.1686 210.4 0.006 269.4 0.519
MB + FBS amyloid spots (20 days) 324.6 154.2 0.0029 133.2 0.0008 191.2 0.27 230.4 0.1934 133.2 0.0008 113.6 0.0002 164.4 0.0055
Medulla + OL (10 days) 459.7 219.2 0.0675 431 0.9996 308.4 0.2195 270.2 0.4465 285.2 0.2961 216.8 0.0635 331.8 0.6279
Medulla ( OL (20 days) 607 321.2 0.0126 304.2 0.0075 419.4 0.1776 175 0.0014 253.8 < 0.0001 202.4 0.0003 225 0.0006
Amyloid aggregation 93.85 23.52 0.0001 24.6 0.0002 56.12 0.0354 44.61 0.005 N/A N/A 26.72 0.0002 33.72 0.0008
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FIGURE 1 | Aβarc flies’ lifespan. (A) Kaplan–Meier survival trajectories of AβArc flies under different drug treatments. (B) Mean survival time of AβArc flies on different
treatments. Kruskal–Wallis test followed by Dunn’s post hoc was used to compare the differences between different groups. Data are expressed as mean ± SEM,
n = 3 (number of independent experiments with a minimum of 100 flies per genotype). P < 0.05 was considered as significant. *P < 0.05; **P < 0.01; ***P < 0.001;
****P < 0.0001. Genotypes: Untreated = Aβarc-expressing flies; Wild Type = elav-Gal4 line; all treated groups are Aβarc-expressing flies fed with the stated drug.
body areas recorded a significant reduction of amyloid spots
in flies treated with both XJP-1 monotherapy and XJP-1 and
memantine combined therapy (Figure 3C). Conversely, none of
the treatments tested had a beneficial impact on the medulla and
optic lobe amyloid spot count (Figure 3D).
To assess whether AD progression alters these amyloid spot
count results, we also analyzed the Aβarc fly brains 20 days
post-eclosion (Figure 4A). The whole brain analysis showed
a significant reduction of the amyloid spot counts, similar
to that observed with XJP-1 at 10 days, in flies treated
with XJP-1, donepezil, and memantine, while galantamine and
rivastigmine failed to show any significant effect (Figure 4B).
The same reduction trends were recorded in the mushroom
bodies and fan-shaped bodies (Figure 4C). Although none of
the treatments tested reduced the amyloid spot counts in the
medulla and optical lobe areas after 10 days (Figure 3D), analysis
of samples treated for 20 days showed a significant decrease
in the amyloid spot levels for all treatment tested, with the
exception of galantamine and rivastigmine (Figure 4D). The
combined therapies investigated, however, did not show any
further beneficial effects than the single therapies (Table 1).
XJP-1 Reduces Amyloid Aggregation via
AChE Inhibition
To confirm that the observed reduction in amyloid spots was
not a result of a reduced quantity of amyloid peptides within
the Aβarc fly brains, we quantified amyloid peptide expression
following 10 and 20 days of treatment. At both time points,
and for all drug treatments, amyloid peptide expression was
statistically similar to the untreated brains (Supplementary
Figure 2). This result is expected since the expression of the
transgene is determined by the UAS/Gal4 system and is not
targeted by any of the drugs studied. We hypothesized that the
AChE enzyme was functioning as a nucleation point for amyloid
peptide aggregation, as previously reported (Inestrosa et al., 1996;
Rees et al., 2003; Lushchekina et al., 2017). We therefore used an
in vitro enzymatic assay to evaluate amyloid peptide aggregation
rate, where amyloid-β peptides carrying the Arctic mutation were
co-incubated with AChE enzyme in the presence, or not, of all
the AChE inhibitors tested. We found a significant drop in all
treatments studied, with the greatest reductions observed for
XJP-1 and donepezil, both recording an almost 80% decrease in
aggregation rate (Figure 5). Once again, the combined therapies
did not result in any further decrease in amyloid aggregation
rate (Figure 5).
DISCUSSION
Over the past 10 years, the fruit fly has emerged as a powerful
in vivo model for neurodegenerative diseases, including AD
(Zhang et al., 2016a; Pham et al., 2018; Ali et al., 2019; Cornelison
et al., 2019; Higham et al., 2019; Hwang et al., 2019; Miyazaki
et al., 2019; Sivanantharajah et al., 2019; Tue et al., 2020).
Transgenic Drosophila AD models have been employed for
a number of drug testing studies involving different targets
such as AChE, GSK-3β, lysozyme, radiation, Tau protein, and
dopaminergic receptors (Sandin et al., 2016; Zhang et al.,
2016a; Pham et al., 2018; Ali et al., 2019; Hwang et al.,
2019; Miyazaki et al., 2019; Zhong et al., 2019). Flies use a
variety of neurotransmitters to communicate between neurons
(e.g., dopamine, GABA, glutamate, acetylcholine, serotonin);
however, differences have been observed in the functions of
these neurotransmitters between invertebrates and vertebrates.
In Drosophila, glutamate is known to be the primary excitatory
neurotransmitter at the NMJ, whereas acetylcholine plays this
role in mammals (Jan and Jan, 1976; Colombo and Francolini,
2019). Conversely, in the mammalian CNS, glutamate is the
primary excitatory neurotransmitter. In flies, acetylcholine is
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FIGURE 2 | Aβarc flies climbing assay. Aβarc flies climbing assay under different treatments. Data show the climbing performance trends over a 21-day period. Data
generated from the climbing index was processed as a percentage of the total. In order to compare vials with a different number of flies, repeated measures analysis
of variance was used to compare climbing scores between treated and untreated groups. (A) Climbing assay of untreated Aβarc flies. (B) Climbing assay of Aβarc
flies treated with XJP-1. (C) Climbing assay of Aβarc flies treated with donepezil. (D) Climbing assay of Aβarc flies treated with rivastigmine. (E) Climbing assay of
Aβarc flies treated with galantamine. (F) Climbing assay of Aβarc flies treated with memantine. (G) Climbing assay of Aβarc flies treated with XJP-1 and memantine.
(H) Climbing assay of Aβarc flies treated with donepezil and memantine. Data are presented in the figure as the mean ± SD; data are compared against the untreated
group. n = 3 (number of independent experiments, each experiment with a minimum of 10 flies per treatment). P < 0.05 was considered as significant. *P < 0.05;
**P < 0.01; ***P < 0.001; ****P < 0.0001.
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FIGURE 3 | Amelioration of amyloid spots in Aβarc flies CNS after 10 days of treatment. (A) Representative confocal images of WT (top left panel) or Aβarc brains;
arrows show amyloid spots; scale bar: 100 µm. (B) Whole brain quantification of amyloid spots. ANOVA test followed by Bonferroni’s post hoc was used to
compare the differences between three or more groups, P < 0.05 was considered as significant. Data are presented as mean ± SEM. n = 3, with a minimum of five
flies per experiment analyzed. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. (C) Mushroom body and fan-shaped body quantification of amyloid spots.
ANOVA test followed by Bonferroni’s post hoc was used to compare the differences between three or more groups, P < 0.05 was considered as significant. Data
are presented as mean ± SEM. n = 3, with a minimum of five flies per experiment analyzed. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. (D) Medulla and
Optic lobe quantification of amyloid spots. ANOVA test followed by Bonferroni’s post hoc was used to compare the differences between three or more groups,
P < 0.05 was considered as significant. Data are presented as mean ± SEM. n = 3, with a minimum of five flies per experiment analyzed. *P < 0.05; **P < 0.01;
***P < 0.001; ****P < 0.0001.
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FIGURE 4 | Amelioration of amyloid spots in Aβarc flies CNS after 20 days of treatment. (A) Representative confocal images of WT (top left panel) or Aβarc brains;
arrows show amyloid spots; scale bar: 100 µm. (B) Whole brain quantification of amyloid spots. ANOVA test followed by Bonferroni’s post hoc was used to
compare the differences between three or more groups, P < 0.05 was considered as significant. Data are presented as mean ± SEM. n = 3, with a minimum of 1 fly
per experiment analyzed. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. (C) Mushroom body and fan-shaped body quantification of amyloid spots. ANOVA
test followed by Bonferroni’s post hoc was used to compare the differences between three or more groups, P < 0.05 was considered as significant. Data are
presented as mean ± SEM. n = 3, with a minimum of 1 fly per experiment analyzed. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. (D) Medulla and Optic
lobe quantification of amyloid spots. ANOVA test followed by Bonferroni’s post hoc was used to compare the differences between three or more groups, P < 0.05
was considered as significant. Data are presented as mean ± SEM. n = 3, with a minimum of five flies per experiment analyzed. *P < 0.05; **P < 0.01; ***P < 0.001;
****P < 0.0001.
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FIGURE 5 | Reduction of AChE-induced Aβ-peptide aggregation rates in the
presence of AChE inhibitors. ANOVA test followed by Bonferroni’s post hoc
was used to compare the differences between three or more groups. Data are
presented as mean ± SEM of n = 3. *P < 0.05; **P < 0.01; ***P < 0.001;
****P < 0.0001.
broadly expressed and is the primary excitatory neurotransmitter
in the CNS, while the role of the glutamatergic system in the
Drosophila brain remains rather ambiguous (Buchner, 1991).
In fact, there is evidence that glutamate can be inhibitory
within certain fly CNS systems, such as in the olfactory and
visual systems (Liu and Wilson, 2013; Molina-Obando et al.,
2019). Although differences in the functions of neurotransmitter
systems should be taken into account when interpreting results,
if using the fly to model neurodegenerative diseases, it should
be noted that it is the damaged cholinergic portion of the
brain that is linked to the development of Alzheimer’s disease,
hence the use of cholinesterase inhibitors to slow disease
development. The ability to use Drosophila as a model for human
neurodegenerative diseases has proven to be, and will continue
to be, a powerful tool to understand and suppress degenerative
mechanisms (Lenz et al., 2013).
In this work, we have demonstrated the capacity of a new
AChE-I compound, XJP-1, to ameliorate amyloid-β deposition
and consequent behavioral phenotypes in the Aβarc transgenic
Drosophila AD model. Treatment with XJP-1 resulted in an
increased survival time of Aβarc flies of more than 10 days,
improving as well the locomotor functions of the transgenic fruit
flies. Similar results were scored by the FDA therapy donepezil,
despite being administrated at a concentration 10-fold higher
than XJP-1, in contrast with previous reports of donepezil being
effective at a concentration as low as 30 µM (Chakraborty et al.,
2011; Pham et al., 2018).
XJP-1 was able to reduce the amyloid spot counts as early as
10 days after commencing the treatment, in crucial areas of the
Drosophila brain for memory and learning functions. Among the
clinically available AChE inhibitors, none of them showed such
an early effect on amyloid spot counts, with only donepezil having
similar results as XJP-1, but after 20 days of administration and
at a concentration more than 10 times higher. This is the first
evidence that XJP-1 therapy results in an overall improvement of
AD symptomatology in vivo.
On the other hand, a combined treatment of XJP-1 and
memantine did not result in further significant improvement
when compared to XJP-1 treatment alone, as well as combined
donepezil and memantine therapy. Combined therapy is usually
only given to patients when they enter an advanced stage of
the disease, when memantine is added to patients already on
donepezil therapy (Tayeb et al., 2012; Parsons et al., 2013).
In our study, all drugs were administrated continuously from
24 h upon eclosion, including combined therapies, giving a
possible explanation on why donepezil with memantine, and
XJP-1 with memantine, did not show any further beneficial
effect when compared to single therapy on this AD model. This
limitation may also explain the weaker efficacy of galantamine
and rivastigmine compared to donepezil, as they are currently
prescribed to Alzheimer’s patients within mild to moderate stages
of AD, while donepezil is given to AD patients at all stages of the
disease, from mild to severe (Haake et al., 2020). Moreover, the
NMDAR antagonist memantine is also administered during all
stages of AD, alone or as combination with donepezil to further
improve the cognitive functions, as efficacy against the amyloid
pathology is still controversial (Folch et al., 2018).
Over the past decade, the efforts to find a cure to AD have
been mainly focused on anti-amyloid agents, such as beta-
secretase 1 (BACE1) inhibitors, assuming that the aggregation
of amyloid-β peptides into plaques is the central triggering
mechanism. However, a number of clinical trials involving this
type of target have failed to produce any significant improvement
(Cummings et al., 2019). Thus, it is necessary to investigate novel
therapeutics for which the mechanism of action involves directly,
or indirectly, multiple targets such as the cholinergic pathway,
amyloid pathology, and Tau hyperphosphorylation. A number of
studies have placed the cholinergic system at the center of the AD
etiopathogenesis, involving the overactivation of crucial enzymes,
such as BACE1 and GSK3-β (Noh et al., 2009; Yoshiyama et al.,
2010; Medeiros et al., 2011; Potter et al., 2011; Kalkman and
Feuerbach, 2016; Zhang et al., 2016a). Our study has shown a
clear involvement of AChE inhibition on amyloid aggregation
resulting in an amelioration of symptoms. The effect of XJP-1 on
Aβarc transgenic flies were partially replicated only by donepezil
at a concentration 10 times higher than our drug candidate, with
XJP-1 having an earlier beneficial effect in reducing the amyloid
spot counts after 10 days of treatment. Other than that, the other
FDA-approved AChE inhibitors, galantamine and rivastigmine,
reduced the amyloid aggregation rate of about 50%, while XJP-
1 and donepezil reduced it by about 80%, potentially explaining
the limited beneficial effects observed in Aβarc flies treated with
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galantamine and rivastigmine. In addition to this, docking
studies carried out on XJP-1 showed a dual-binding property
for both the PAS and CAS of the AChE enzyme (Wang et al.,
2015), which may further justify the low dosage needed to
slow down the amyloid aggregation, since the PAS of AChE
has been linked to increased amyloid-β peptide aggregation
rate (Inestrosa et al., 1996). Despite not being tested in this
study, XJP-1 has been predicted to have anti-inflammatory
and anti-oxidant properties due to its natural product-derived
structure, which may have also played a role in ameliorating
the AD symptomatology in Aβarc flies (Wang et al., 2015,
2018).
Taken together, the results of these experiments suggest
that XJP-1 ameliorates AD symptomatology by indirectly
reducing amyloid aggregation via AChE inhibition. Despite
XJP-1 showing promising efficacy with this AD model,
further studies will be necessary to investigate whether XJP-
1 results can be translated into mammalian models and
whether treatment can also improve Tau-related phenotypes
presented by AD patients.
CONCLUSION
This work demonstrates that XJP-1 is an effective and potent AD
drug candidate, which efficiently rescues AD symptoms in an
Aβarc fly model, with earlier effects at a much lower concentration
than observed for any of the currently approved therapies. This
includes a significant improvement in locomotor defects and
lifespan. By inhibiting AChE, XJP-1 indirectly reduced amyloid
aggregation and therefore also the number of amyloid spots
detected at an earlier stage in Aβarc Drosophila brains.
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Supplementary Figure 1 | Representative images of cholinergic neurons network
in Drosophila Melanogaster brain obtained from the Virtual Fly Observatory. (A)
Cholinergic neurons within the mushrooms bodies. (B) Cholinergic neurons within
the fan-shaped bodies. (C) Cholinergic neurons within the medulla. (D)
Cholinergic neurons within the optic lobes. (E) Cholinergic neurons within the
antennal lobes. (F) Cholinergic neurons within the subesophageal ganglion.
Supplementary Figure 2 | Amyloid peptides quantity in Aβarc flies’ heads. (A)
Representative images of WB membranes showing amyloid peptides quantity after
10 and 20 days of treatment. (B) AβArc peptide quantification by membrane image
analysis. ANOVA test followed by Bonferroni’s post hoc was used to compare the
differences between different groups. Data are presented as mean ± SEM, n = 3
(number of independent experiments with 50 fly heads per treatment group).
P < 0.05 was considered as significant. ∗P < 0.05; ∗∗P < 0.001; ∗∗∗P < 0.0001.
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